Skip to Content
COVID-19 Response and Update
International
Amneal Pharmaceuticals
  • Corporate
  • India
  • About
        • AboutWe challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Program
          • Product Donations
          • National and Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson’s
        • Awards & Recognition
  • Products
        • ProductsWe create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & DevelopmentWe invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • InvestorsBecome an Informed Investor
        • Financial Reports
          • SEC Filings
          • Annual Reports
          • Quarterly & Other Reports
        • Events & Presentations
        • Stock Information
        • Corporate Governance
          • Policies
          • Executive Officers & Directors
          • Board Committees
        • Investor Resources
          • Analysts
          • Investor FAQ
          • Email Alerts
          • Information Request
          • RSS Feeds
  • News
  • Careers
        • CareersHelp make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login

Specialty R&D

Our innovations meet important medical needs

Our Specialty portfolio delivers innovative medicines focused on meeting important medical needs across therapeutic categories, including central nervous system disorders (Parkinson’s Disease, Spasticity, Migraine), endocrinology (Hypothyroidism), and other therapeutic areas.

We are focused on the continued growth and expansion of our product portfolio through internal development as well as through acquisitions and late-stage and next-generation product partnership opportunities.

Clinical Activities

Flow Chart of Clinical Activities


Product


Indication


Estimated Launch

IPX203


Parkinson’s Disease


2024*

DHE Autoinjector


Migraine and Cluster Headache


Q1 2025

K-127


Myasthenia Gravis


2025

K-114


Hypothyroidism


2026-2027

K-130


Neurogenic Orthostatic Hypotension


2027

*Pending completion of a requested QT safety study to resolve CRL and FDA approval
**As of November 2023

Drug Delivery Technologies
Drug Delivery Technologies
  • Privacy Notice
  • Copyright & Legal Disclaimer
  • Web Accessibility
  • Expanded Access Policy
  • NABP DDA Accreditation
  • Linkedin
  • Twitter
  • Youtube
© 2023 Amneal Pharmaceuticals LLC.
All rights reserved.